drugset
drugset / Trial / NCT04659239

The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19

NCT04659239 ↗

Phase 3 Unknown 34020 enrolled Chinese Academy of Medical Sciences
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a randomized, double-blinded, placebo controlled phase III clinical trial to evaluate the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above after 2-dose schedule.

Timeline

Start
2021-01-28
Primary completion
2021-09
Completion
2022-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Inactivated SARS-CoV-2 vaccine (Vero cell) Vaccine 0.5 ml —

Indications

COVID-19